Quintiles to hire 500 for new BPO hub in China

Underscoring the global shift of clinical development work to the East, Quintiles has mapped out plans to open its fourth hub in China with plans to hire 500 workers for a new business process outsourcing operation that will cater to a broad range of biopharma clients with a multilingual staff based in Dalian. The move comes just weeks after Quintiles announced plans to set up a new CRO based in Beijing.

In addition to supporting clinical operations at study sites scattered through the region, Durham, NC-based Quintiles plans to offer regional as well as global clients help with data management, biostatistics, medical writing, pharmacovigilance, post-marketing safety surveillance and back-office support.

"Following the success of Quintiles' Bangalore BPO center, which has over 1,000 people supporting global studies, the Dalian Center of Excellence will provide a North Asia support structure for our growing business in Japan, Korea and China," said Anand Tharmaratnam, senior vice president and head of Asia markets. Quintiles will provide clinical services in English, Japanese, Korean and Mandarin.

China has been one of the world's top emerging markets for Big Pharma. And drug developers of every stripe have been eyeing the country's growing outsourcing offerings as CROs flock to the region.

- here's the press release

Related Articles:
Quintiles launches CRO in booming China drug market
Quintiles CEO: China could replace U.S. as biotech leader

Suggested Articles

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.

The €875 million deal gives Sanofi global rights to therapies that could mitigate an efficacy-limiting shortcoming of anti-CD38 antibodies.

Two years after its official launch, next-gen cancer biotech Foghorn Therapeutics has nabbed a biobucks deal with Big Pharma Merck.